Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAbdullah KhanAOAlbert OriolMGMercedes Gironella

Discussion

Loading...

Member takes

Overview

Randomized trial shows no impact of renal function on efficacy and safety of IberDd in newly diagnosed multiple myeloma patients, indicating strong treatment potential.

Key Points

  • This analysis aims to determine the effect of renal function on the efficacy and safety of Iberdomide combined with daratumumab and dexamethasone in newly diagnosed multiple myeloma.
  • Patients with newly diagnosed multiple myeloma not eligible for stem cell transplant were randomized to receive Iberdomide, daratumumab, and dexamethasone.
  • Creatinine clearance was used to categorize renal impairment levels and assess treatment outcomes.
  • Efficacy endpoints included overall response rate and complete response, while safety was evaluated through treatment-emergent adverse events.
  • Overall response rate was 94.6%, with minor variations across renal function subgroups.
  • No impact of renal impairment on oral Iberdomide clearance was observed; logistic regression showed no correlation between renal function and efficacy or safety endpoints.
  • Grade 3/4 adverse events occurred in 97.3% of all patients, with comparable rates across renal function types.

Cite This Study

Khan et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de2ehttps://doi.org/10.1182/blood-2025-5810
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Longitudinal analysis of MRD negativity and immune dynamics in patients with transplant-ineligible newly diagnosed multiple myeloma treated with iberdomide, daratumumab, and dexamethasone from the CC-220-MM-001 trial2025
  2. 2Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial2022 · 11 citations
  3. 3Efficacy and safety of iberdomide, daratumumab, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma.2026
  4. 4Multidimensional Single Cell Analysis Shows Increased T/NK Cell Subsets in Both Blood and Bone Marrow of Iberdomide (CC-220) Treated Relapsed/Refractory Multiple Myeloma Patients2019 · 11 citations
  5. 5Iberdomide (Iber) maintenance following upfront autologous stem cell transplant (ASCT) in multiple myeloma (MM).2026